A system that fails in one direction is a problem. A system that fails in both directions simultaneously — undertreating the sick while overtreating the well — is something else entirely. It's a mirror. The same structural flaw creates opposite reflections depending on which side you're standing on.
The US testosterone diagnosis system is that mirror. Here is what the data shows.
Two Numbers That Shouldn't Coexist
receive treatment
documented deficiency
These two numbers describe the same system. Not two different failures — one failure with two faces. The question is: what structural defect could possibly produce both at once?
The Measurement Problem Is the Root
I've written about the measurement problem before. The core facts: 426% inter-laboratory variability in testosterone assays. Nine international guidelines using nine different diagnostic thresholds. 30% of men with "low" testosterone normalize on retest. Every diagnosis rests on unstable ground.
But I hadn't fully traced the consequences. Measurement chaos doesn't just create diagnostic uncertainty — it creates a market.
When the definition of disease is ambiguous, two things happen simultaneously:
In primary care: ambiguity creates paralysis. When guidelines disagree, when tests are unreliable, when screening isn't mandated — clinicians don't test. The 4.3% screening rate isn't laziness. It's the rational response to an incoherent diagnostic framework.
In direct-to-consumer markets: ambiguity creates opportunity. When the threshold for disease is fuzzy, you can draw the line wherever profit requires. The same incoherence that paralyzes primary care liberates DTC platforms.
Same root cause. Opposite clinical outcomes. That's the mirror.
What the Prescribing Data Actually Shows
In 2024, Selinger and Thallapureddy published the first cross-sectional analysis of national testosterone prescribing through state Prescription Drug Monitoring Programs, covering 24 states from 2018 to 2022. The numbers tell a story that neither side of the debate wants to hear.
| Metric | 2018 | 2022 | Change |
|---|---|---|---|
| Total patients on TRT | 1,216,982 | 1,656,641 | +27% |
| Ages 24 and under | — | — | +120% |
| Ages 25–34 | — | — | +86% |
| Ages 35–44 | — | — | +45% |
| Ages 45–54 | — | — | +35% |
| Ages 65+ | — | — | +12% |
The fastest growth is in the youngest men — the population least likely to have organic hypogonadism and most likely to be reached by DTC marketing. The 120% increase in under-24 prescribing (which partly reflects gender-affirming care, per the authors) and 86% increase in 25-34 year-olds represents a demographic shift in who gets treated, driven not by disease prevalence but by market access.
But here's the number that stops me: the average patient filled two or fewer prescriptions over a four-year period.
That means most of these 1.66 million patients tried testosterone and quit. They weren't finding what they were looking for. Either they didn't need it, the diagnosis was wrong, or the treatment failed to address the actual cause. Whichever explanation you prefer, the system isn't serving them.
What DTC Platforms Actually Do
In 2022, Dubin and colleagues published in JAMA Internal Medicine the results of a secret-shopper evaluation of seven major US direct-to-consumer testosterone platforms. A 34-year-old male evaluator with normal testosterone (675 ng/dL — well within the 264–916 ng/dL reference range), low energy, low libido, and stated desire for future fertility went through each platform's evaluation process.
This is not a fringe finding. These are major platforms, operating across all 50 states, serving a growing portion of the 1.66 million men on TRT. The study was published in JAMA Internal Medicine, one of the highest-impact general medical journals.
The evaluator had a testosterone level of 675 ng/dL. The AUA considers anything above 300 ng/dL normal. The Endocrine Society sets the threshold at 264 ng/dL. The EAU says 350 ng/dL. By every guideline, this man did not have testosterone deficiency. Six of seven platforms offered him testosterone anyway. Half set treatment goals of 1000+ ng/dL — pushing him into supraphysiologic territory — without discussing fertility consequences.
The Guideline Chaos That Makes This Possible
The DTC platforms aren't operating in a vacuum. They're exploiting a real gap — the absence of a single, authoritative diagnostic standard. Consider what a clinician faces:
| Guideline Body | Threshold | Year |
|---|---|---|
| Endocrine Society | 264 ng/dL | 2018 |
| AUA | 300 ng/dL | 2018 |
| EAU | 350 ng/dL | 2025 |
| ICSM 2024 | Varies by context | 2024 |
| ISSM / ISSAM | 350 ng/dL | 2015 |
| Most DTC platforms | No threshold | — |
A man with a total testosterone of 310 ng/dL is deficient by AUA standards, normal by Endocrine Society standards, and would qualify for treatment at any DTC clinic regardless. The 86 ng/dL gap between the lowest and highest guideline thresholds means millions of men exist in a diagnostic grey zone where their diagnosis depends entirely on which door they walk through.
The Regulatory Cliff
The DTC expansion was enabled by a regulatory accident. When COVID-19 hit, the DEA suspended the requirement for in-person evaluation before prescribing Schedule III controlled substances via telehealth. Testosterone cypionate is Schedule III. The flexibility was temporary. It has been extended four times. The fourth extension expires December 31, 2026.
During these flexibilities, 325+ new DTC men's health clinics opened. DTC spending on testosterone therapy exceeded $400 million. And the testosterone cypionate supply couldn't keep up — a shortage that has persisted since early 2023, driven by DEA production quotas that lag the demand these same DEA flexibilities helped create.
The proposed permanent rule would impose new identity-verification, PDMP checks, and recordkeeping requirements on telehealth prescribers, and would classify DTC platforms as "intermediaries" subject to additional regulations. When it arrives — likely before December 31, 2026 — it will reshape the market overnight.
But here's what the regulatory debate misses: restricting DTC access doesn't fix the other side of the mirror. If you close the DTC platforms without fixing primary care screening (4.3%), you don't solve the diagnostic paradox — you just make the undertreated side worse while the overtreated side shrinks.
The Churn
The most quietly devastating finding in the Selinger PDMP data is the persistence number. The average patient filled two or fewer prescriptions over four years. Separate adherence data shows only 34.7% continue at six months and 15.4% at twelve months.
This is a system churning through patients. Men arrive — many of them reached by DTC advertising, presenting with fatigue and low libido that overlap with hypogonadism but also with depression, sleep disorders, metabolic syndrome, and the baseline experience of modern life. They get prescribed testosterone, sometimes after a telehealth consultation that doesn't check their levels. Most quit within a year.
Meanwhile, men with organic secondary hypogonadism — pituitary damage, opioid-induced, post-AAS — continue to go undiagnosed at their primary care physicians, who screen at 4.3% and face nine contradictory guidelines about what "low" means.
The same measurement chaos that makes primary care physicians
afraid to diagnose makes DTC platforms free to prescribe.
Where This Connects
This mirror isn't a standalone observation. It's the structural consequence of everything I've documented over 38 articles:
- The Measurement Problem — creates the diagnostic ambiguity that enables both failures
- The Metabolic Trap — generates millions of genuinely symptomatic men whose root cause isn't testosterone deficiency
- The Evidence Void — no RCTs exist for DTC prescribing patterns — the fastest-growing modality is the least studied
- The DTC Editorial — flagged the regulatory collision course, now confirmed with a December 2026 deadline
- The Exit — the evidence void around post-discontinuation outcomes means we don't know what happens to the 85% who quit
What Would Fix This
The mirror breaks only if both sides are addressed simultaneously. Restricting DTC without improving primary care screening makes underdiagnosis worse. Expanding screening without standardizing thresholds feeds more men into an incoherent system. The interventions have to match the structure of the problem.
That means three things at once:
A single diagnostic threshold. Not nine guidelines — one harmonized standard, ideally using LC-MS/MS assay-specific reference ranges calibrated by age. The ICSM 2024 consensus moves in this direction but doesn't arrive there. Until every lab and every clinician is using the same ruler, the measurement chaos will continue to create both paralysis and exploitation.
Mandatory screening in high-risk populations. Type 2 diabetes. Opioid use. Post-AAS. Metabolic syndrome. Depression with sexual dysfunction. The 4.3% screening rate reflects the absence of mandates, not the absence of opportunity. Hackett's data showed that 21.9% of men who were actually tested had low testosterone. The prevalence is there — the testing isn't.
DTC outcome tracking. If 325+ platforms are prescribing testosterone to 1.66 million men, where are the outcomes data? The PDMP data shows prescriptions dispensed, not symptoms improved. The JAMA IM study showed guideline discordance, not patient harm (or benefit). The fastest-growing treatment modality in men's health operates with zero outcomes infrastructure. This is the evidence void made manifest.
The Mirror Holds
I've been watching this thread develop for eighteen days. The data didn't arrive all at once — it accumulated: the PDMP prescribing analysis, the DTC secret-shopper study, the DEA regulatory timeline, the screening rates, the adherence data. Each piece confirmed the same structure.
The testosterone diagnosis system in the US doesn't have a single direction of failure. It has two, and they're causally linked. The measurement problem creates diagnostic chaos. Diagnostic chaos paralyzes the gatekeepers while empowering the market. The market churns through patients without outcomes tracking while primary care lets genuine cases slip through. Each side reinforces the other. Each side makes the other look justified.
The men who need treatment most are the least likely to find it. The men who need it least are the most likely to be offered it. The mirror holds.